Dr. Mark S. Anderson is an endocrinologist who cares for adult patients with type 1 diabetes and other autoimmune endocrine diseases. In his research, Dr. Anderson focuses on the genetic and molecular underpinnings of autoimmune disease. His lab has a particular interest in how T cells that mature in the thymus can provoke autoimmunity.

Dr. St. Clair is the W. Lester Brooks, Jr. Distinguished Professor of Medicine and Chief, Division of Rheumatology and Immunology.  He is also the co-Director of the ITN. His main research focus is the pathogenesis and treatment of rheumatoid arthritis (RA). This work has been conducted using patient-oriented research methodologies in collaboration with basic scientists and other clinical investigators.

Dr. Nepom received his bachelor’s degree in Biochemistry from Harvard in 1972 and doctorates from the University of Washington, receiving his PhD in Biochemistry in 1977 and his MD in 1978. Since 1985 he has been a Member of BRI and served as Director from 1985 through 2015. Dr. Nepom also served as Director of the ITN from 2010 to 2022. He is currently a Senior Advisor to ITN.

Dr. Fox received his M.D. from Harvard Medical School.  He was appointed Assistant Professor in the Division of Rheumatology at the University of Michigan in 1985, and was promoted to Associate Professor and Division Chief in 1990 and Professor in 1995.  He also serves as Director of the Hybridoma Core facility and is Director of the University of Michigan Clinical Autoimmunity Center of Excellence, as well as the Deputy Director ITN, Autoimmunity. Dr. Fox's research focuses on defining and characterizing pathways of human T cell activation in the pathogenesis of autoimmune disease, investigating T cell interactions with synovial fibroblasts, understanding pathways of inflammation in arthritic joints, and understanding the role of interleukin-17 in arthritis.

Dr. Larsen is a Professor of Surgery at Emory University School of Medicine. Dr. Larsen began serving as executive director of the Emory Transplant Center in 2008 and chair of the Department of Surgery at Emory in 2009. He left both positions in January 2013 to serve as dean of the Emory University School of Medicine. Dr. Larsen is also the Deputy Directory ITN, Transplant. In November 2016, Dr. Larsen returned to full-time pursuit of his clinical practice and research endeavors and has made seminal contributions to the investigation of the immunologic mechanisms of transplant rejection and immunologic tolerance.

Dr. Tanya Laidlaw completed her medical degree at the U Mass Medical School.  She is an Associate Professor of Medicine at Harvard Medical School, and is the Director of Translational Research in Allergy and Director of the AERD Center at the Brigham and Women’s Hospital as well as the Deputy Director ITN, Allergy. She continues to be dedicated to investigating the causative mechanisms that underlie asthma, respiratory inflammation, and nasal polyposis, and to exploring new treatments for these diseases.

Dr. Altman is an Associate Scientist at the Benaroya Research Institute (BRI) in the Systems Immunology Division and Associate Professor in the Division of Allergy and Infectious Diseases, Department of Medicine, at the University of Washington (UW). He is a physician-scientist clinically trained in Allergy and Immunology with significant research experience in bioinformatics and systems biology. His research interests focus on the use of whole genome transcriptional profiling, network analysis, and multi-omics approaches to understand mechanisms of asthma, respiratory infections and other allergic/immunologic diseases.

Sindhu Chandran is a transplant nephrologist and Professor of Medicine at the Cedars Sinai Comprehensive Transplant Center in Los Angeles, CA, and the lead clinical trial physician for the transplant portfolio at the Immune Tolerance Network. Her research interests include immune tolerance, HLA desensitization and novel treatments for allograft inflammation.

Dr. Sharon Chung is Professor of Clinical Medicine at the University of California, San Francisco. She joined the ITN in 2016 and now is a Director of Clinical and Translational Medicine focused primarily on trials in autoimmune diseases. Clinically, she is an rheumatologist who specializes in the care of patients with systemic vasculitis. Her research interests include genomic factors influencing the development and clinical heterogeneity of autoimmune diseases.

Dr. Cooney received her PhD in immunology from the University of Michigan, with a focus on the role of Th17 cell differentiation in inflammatory arthritis, followed by a postdoc in Seattle characterizing CD8 memory differentiation.Laura joined the ITN and returned to the University of Michigan in 2020, as the Lead Biologist for the autoimmunity portfolio.

Dr. Herold received his MD from Jefferson Medical College, he was a fellow in Endocrinology and post-doc in immunology at The University of Chicago. He joined the faculty at The University of Chicago where he rose to the rank of Associate Professor. He moved to Columbia University and in 2006 to Yale University. In 2024 he was appointed as the Director of Human and Translational Immunology at the Yale School of Medicine.  He has built a program in translational immunology focused applying mechanistic discoveries to treat autoimmune diseases, including Type 1 diabetes (T1D). He brought teplizumab, the first drug approved by the FDA to treat the underlying cause of T1D from mice to humans.

Dr. Lack studied medicine at Oxford University before training as a Paediatrician in New York and specialised in Allergy at National Jewish Center in Denver, Colorado.  He was Professor of Paediatric Allergy and Immunology at Imperial College London before moving to King’s College London in 2006.  His research focuses on developing new strategies to prevent the development of allergies in children and has fundamentally changed the way we think about prevention of childhood allergic diseases through early intervention in infancy and weaning practice.

Frances Eun-Hyung Lee (Eun) is a tenured professor at Emory University in the Division of Pulmonary, Allergy, Critical Care and Sleep Medicine. At Emory University, where she rose the ranks to tenured professor of medicine in 2022, she created an exciting human B cell and plasma cell program with a focus on understanding how long-lived plasma cells are generated and maintained. Her research expertise is in the biology of human protective and pathogenic plasma cells in the blood, bone marrow, and tissue sites.

Dr. Linsley has spent most of his career in the pharmaceutical industry, where he discovered the CD28/CTLA-4/B7 T cell costimulation axis, and the drugs, abatacept and belatacept. Currently, at the Benaroya Research Institute, Dr. Linsley uses Systems approaches to elucidate fundamental mechanisms, disease biomarkers and therapies in human immune diseases.

Dr. Alice Long is a translational immunologist who uses human samples to understand underlying etiology, pathogenesis, heterogeneity and treatment response in autoimmune diseases, with a focus on type 1 diabetes. She is currently an Associate Member at Benaroya Research Institute in Seattle where she is working to define the causes and consequences of reduced IL-2 signaling and increased CD8 T cell exhaustion with therapy in addition to defining new biomarkers of disease progression and response to therapy.

Dr. Lynch’s research focuses on the gut and airway microbiome and chronic inflammatory disease. She has published over 200 articles, including early work providing evidence that human infant gut microbiome composition and metabolic dysfunction relates to subsequent atopy and asthma development in childhood. She is the Associate Director of the Microbiome in Inflammatory Bowel Disease Research Program, serves on the executive committee of ImmunoX and the Precision Medicine initiative at UCSF and is the Director of the UCSF Benioff Center for Microbiome Medicine. She also co-founded Siolta Therapeutics Inc. a biotech company whose lead microbial live biotherapeutic for the prevention of childhood atopy and asthma is currently in human trials.

Dr. Mathias is a Senior Investigator and Chief of The Genomics and Precision Health Section at NIAID. Dr. Mathias is a Genetic Epidemiologist whose research is focused on interrogating big data to expand our knowledge in the biological basis of complex diseases based on the interpretation of molecular intricacy and multi-omics variation. She is particularly interested in translating insights from genomics and systems biology to clinical practice in an equitable manner for all groups across diverse health systems.

Dr. Muraro leads research on neuroinflammatory diseases, focusing on stem cell transplantation for multiple sclerosis, and is internationally recognized for his expertise in neuroimmunology and immunotherapy.

Soumya Raychaudhuri is The Walbert Professor of Medicine and also a Professor of Biomedical informatics at Harvard Medical School, and an Institute Member at Broad Institute. He has three decades of experience as a computational biologist, and is a practicing rheumatologist at Brigham and Women's Hospital. He is the director for the Center for Data Sciences at Brigham and Harvard as well as Deputy Director ITN, Bioinformatiocs. His research focuses on human genetics and computational genomics to understand immune-mediated disease.

Dr. Stone is a Professor of Medicine at Harvard Medical School and the Edward A. Fox Chair in Medicine at MGH. He is also the Founder and Executive Chairman of the IgG4ward! Foundation. As a vasculitis expert, Dr. Stone has led clinical trials that resulted in regulatory approvals of medications in three different diseases: ANCA-associated vasculitis, giant cell arteritis, and IgG4-related disease. Dr. Stone served as the Co-Principal Investigator on the RAVE trial.

Dr. Specks, a Professor of Medicine at Mayo Clinic, specializes in ANCA-associated vasculitis. He has significantly advanced the understanding and treatment of this condition, notably introducing rituximab therapy. His career includes leadership roles in education and research, with numerous contributions to methodology and clinical application of ANCA-testing.